Contact The Gross Law Firm by September 15, 2025 Deadline to Join Class Action Against Capricor Therapeutics, Inc.(CAPR)

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its lead cell therapy candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [2][4] Group 1: Allegations and Impact - The lawsuit claims that Capricor provided investors with overly positive information about its ability to obtain a Biologics License Application (BLA) from the FDA while concealing adverse facts about the safety and efficacy data from its Phase 2 HOPE-2 trial [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness and the need for additional clinical data, Capricor's stock price dropped from $11.40 to $7.64 per share [2] Group 2: Class Action Details - The class period for the lawsuit is defined as October 9, 2024, to July 10, 2025, and shareholders are encouraged to register for participation by September 15, 2025 [3] - Shareholders who register will receive updates on the case's progress through portfolio monitoring software, and there is no cost or obligation to participate [3] Group 3: Law Firm Information - The Gross Law Firm, which is leading the class action, is recognized for protecting investors' rights against deceit and fraud, aiming to recover losses incurred due to misleading statements by companies [4]